Overview
According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and/or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment/care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.
Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed/granted in the past few years, demonstrating the continued innovation being carried out in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years.
Scope of the Report
The “Novel Ocular Drug Delivery Devices Market by Type of Drug Delivery Device (Implants, Inserts and Punctal Plugs), Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet Age-related Macular Degeneration, Retinal Diseases, Neovascular Age-Related Macular Degeneration and Others), Type of Product (Biodegradable and Non-biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain.
Amongst other elements, the report includes:
- A detailed assessment of the current market landscape of novel ocular drug delivery devices, with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I/II, phase I and preclinical), type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).
- Elaborate profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.
- An in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.
- An analysis of the partnerships that have been established in this domain during the period 2012-2021 covering R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and other related agreements.
- An analysis of the investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
- An in-depth analysis of over 1,100 patents filed/granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed/granted), patent benchmarking and valuation.
- A case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers and others.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel ocular drug delivery devices over the coming decade. Additionally, it features market size projections for the overall novel ocular drug delivery devices market, wherein both the current and upcoming opportunity is segmented across [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indications (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
- Eyal Sheetrit (Chief Executive Officer and President, Eximore)
- Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea)
Key Questions Answered
- Who are the leading novel ocular drug delivery device developers?
- Which are the popular types of novel ocular drug delivery devices available in this market?
- What are the key challenges faced by stakeholders engaged in this domain?
- What types of partnership models are commonly being adopted by stakeholders in this industry?
- Who are the key investors in this domain?
- How is the intellectual property landscape in this field likely to evolve in the foreseen future?
- What are the factors that are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Eye
3.3. Routes for Ocular Drug Delivery
3.4. Ocular Drug Delivery Systems
3.4.1. Dendrimers
3.4.2. Hydrogels
3.4.3. Liposomes
3.4.4. Nanomicelles
3.4.5. Nanoparticles
3.5. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Novel Ocular Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Drug Delivery Device
4.2.2. Analysis by Current Status of Development
4.2.3. Analysis by Type of Drug Delivery Device and Current Status of Development
4.2.4. Analysis by Type of Product
4.2.5. Analysis by Type of Drug Delivery Device and Type of Product
4.2.6. Analysis by Type of Molecule
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Route of Administration
4.3. Novel Ocular Drug Delivery Devices: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Industry Players: Analysis by Number of Devices
5. CASE STUDY: TYPES OF NOVEL OCULAR DRUG DELIVERY DEVICES
5.1. Chapter Overview
5.2. Novel Ocular Drug Delivery Devices
5.2.1. Bionic Eye
5.2.1.1. Working of a Bionic Eye
5.2.2. Intra Ocular Lenses
5.2.2.1. Evolution of Intra Ocular Lenses
5.2.2.2. Applications of Intra Ocular Lenses
5.2.2.3. Types of Intra Ocular Lenses
5.2.2.4. Classification of Intra Ocular Lenses
5.2.3. Eye Drop Dispenser Devices
5.3. Other Novel Ocular Drug Delivery Systems
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Alimera Sciences
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Product Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Bausch and Lomb
6.3.1. Company Overview
6.3.2. Technology Overview
6.3.3. Product Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. EyePoint Pharmaceuticals
6.4.1. Company Overview
6.4.2. Technology Overview
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Genentech
6.5.1. Company Overview
6.5.2. Technology Overview
6.5.3. Product Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Glaukos
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.3. Product Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. Neurotech Pharmaceuticals
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.3. Product Portfolio
6.7.4. Recent Developments and Future Outlook
6.8. Ocular Therapeutix
6.8.1. Company Overview
6.8.2. Technology Overview
6.8.3. Product Portfolio
6.8.4. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Novel Ocular Drug Delivery Devices: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2 Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Enrolled Patient Population
7.3.5. Analysis by Enrolled Patient Population and Phase of Development
7.3.6. Analysis by Study Design
7.3.7. Analysis by Target Patient Segment
7.3.8. Analysis by Target Indication
7.3.9. Analysis by Type of Sponsor
7.3.10. Most Active Players: Analysis by Number of Registered Trials
7.3.11. Analysis by Number of Registered Trials and Geography
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Novel Ocular Drug Delivery Devices: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Analysis by Geography
8.3.5.1. Region-wise Distribution
8.3.5.2. Country-wise Distribution
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. Novel Ocular Drug Delivery Devices Market: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Analysis by Type of Investor
9.3.7. Most Active Investors: Analysis by Number of Funding Instances
9.3.8. Analysis by Geography
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Novel Ocular Drug Delivery Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geography
10.3.3. Analysis by CPC Symbols
10.3.4 Emerging Focus Areas
10.3.5. Analysis by Type of Drug Delivery Device
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Players: Analysis by Number of Patents
10.4. Novel Ocular Drug Delivery Devices: Patent Benchmarking Analysis
10.4.1 Analysis by Patent Characteristics
10.5. Novel Ocular Drug Delivery Devices: Patent Valuation Analysis
10.6. Leading Patents: Analysis by Number of Citations
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Ocular Drug Delivery Devices Market, 2021-2030
11.3.1. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Drug Delivery Device
11.3.1.1. Novel Ocular Drug Delivery Devices Market for Implants, 2021-2030
11.3.1.2. Novel Ocular Drug Delivery Devices Market for Inserts, 2021-2030
11.3.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs, 2021-2030
11.3.2. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Target Indication
11.3.3. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Product
11.3.4. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Geography
11.3.4.1. Novel Ocular Drug Delivery Devices Market in North America, 2021-2030
11.3.4.1.1. Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030
11.3.4.1.2. Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030
11.3.4.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030
11.3.4.2. Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030
11.3.4.2.1. Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030
11.3.4.2.2. Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030
11.3.4.2.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030
11.3.4.3. Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030
11.3.4.3.1. Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030
11.3.4.3.2. Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030
11.3.4.3.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030
11.3.4.4. Novel Ocular Drug Delivery Devices Market Rest of the World, 2021-2030
11.3.4.4.1. Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030
11.3.4.4.2. Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030
11.3.4.4.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Eximore
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Eyal Sheetrit, Co-Founder and Chief Executive Officer
13.3. Oculinea
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Murty Vyakarnam, Co-Founder and Chief Executive Officer
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Overview of Market Landscape and Developer Landscape
Figure 2.2 Executive Summary: Clinical Trial Activity and Partnership Activity
Figure 2.3 Executive Summary: Funding and Investment Analysis and Patent Analysis
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Structure of the Eye
Figure 3.2 Layers of Tissues in the Eye
Figure 3.3 Types of Ocular Drug Delivery Systems
Figure 3.4 Marketed Ocular Drug Delivery Implants
Figure 4.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Figure 4.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Figure 4.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Figure 4.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Figure 4.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Figure 4.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Figure 4.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Figure 4.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Figure 4.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Figure 4.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Figure 4.12 Key Industry Players: Distribution by Number of Devices
Figure 5.1 Bionic Eye: External and Implantable Modules
Figure 5.2 Visual Prosthesis: Mode of Operation
Figure 5.3 Evolution of Intraocular Lenses
Figure 5.4 Applications of Bandage Intraocular Lenses
Figure 7.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Figure 7.2 Clinical Trial Analysis: Distribution by Phase of Development
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011 - 2021
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Distribution by Geography
Figure 8.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Most Active Players: Distribution by Number of Partnerships
Figure 8.5 Partnerships and Collaborations: Distribution by Region
Figure 8.6 Partnerships and Collaborations: Distribution by Country
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Figure 9.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding (USD Million)
Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
Figure 9.7 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.8 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.9 Funding and Investment Analysis: Distribution by Geography
Figure 10.1 Patent Analysis: Distribution by Patent Filed
Figure 10.2 Patent Analysis: Distribution by Year of Publication, 2002-2021
Figure 10.3 Patent Analysis: Distribution by Location of Patent Jurisdiction
Figure 10.4 Patent Analysis: Distribution by Jurisdiction
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Patent Analysis: Emerging Focus Areas
Figure 10.7 Patent Analysis: Distribution by Type of Drug Delivery Device
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Novel Ocular Drug Delivery Devices: Patent Valuation
Figure 11.1 Global Novel Ocular Drug Delivery Devices Market, 2021-2030 (USD Million)
Figure 11.2 Novel Ocular Drug Delivery Market for Implants, 2021-2030 (USD Million)
Figure 11.3 Novel Ocular Drug Delivery Market for Inserts, 2021-2030 (USD Million)
Figure 11.4 Novel Ocular Drug Delivery Market for Punctal Plugs, 2021-2030 (USD Million)
Figure 11.5 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Figure 11.6 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Figure 11.7 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Figure 11.8 Novel Ocular Drug Delivery Devices Market in North America, 2021-2030 (USD Million)
Figure 11.9 Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030 (USD Million)
Figure 11.10 Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030 (USD Million)
Figure 11.11 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030 (USD Million)
Figure 11.12 Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030 (USD Million)
Figure 11.13 Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030 (USD Million)
Figure 11.14 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030 (USD Million)
Figure 11.15 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030 (USD Million)
Figure 11.16 Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030 (USD Million)
Figure 11.17 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030 (USD Million)
Figure 11.18 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030 (USD Million)
Figure 11.19 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030 (USD Million)
Figure 11.20 Novel Ocular Drug Delivery Devices Market in Rest of the World, 2021-2030 (USD Million)
Figure 11.21 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030 (USD Million)
Figure 11.22 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030 (USD Million)
Figure 11.23 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030 (USD Million)
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Clinical Trial Analysis
Figure 12.3 Concluding Remarks: Partnerships and Collaborations
Figure 12.4 Concluding Remarks: Funding and Investment Analysis
Figure 12.5 Concluding Remarks: Market Forecast
List Of Tables
Table 3.1 Routes for Ocular Drug Delivery
Table 4.1 Novel Ocular Drug Delivery: Overall Market Landscape
Table 4.2 Novel Ocular Drug Delivery Devices: List of Developers
Table 5.1 Bionic Eye Systems: Information on Device Developer, Headquarters, Target Indication and Site of Implant Placement
Table 5.2 Advantages and Disadvantages of Different Types of Intraocular Lenses
Table 5.3 Therapeutic Intraocular Lenses: Information on Developer, Headquarters, Target Indication and Type of product
Table 5.4 Eye-Drop Dispenser Devices: Information on Developer, Headquarters and Target Site
Table 5.5 Other Novel Ocular Drug Delivery Devices: Information on Technology, Type of Product, Developer, Year of Establishment, Company Size and Headquarters
Table 6.1 List of Companies Profiled
Table 6.2 Alimera Sciences: Company Overview
Table 6.3 Alimera Sciences: Technology Overview
Table 6.4 Alimera Sciences: Product Portfolio
Table 6.5 Alimera Sciences: Recent Developments and Future Outlook
Table 6.6 Bausch and Lomb: Company Overview
Table 6.7 Bausch and Lomb: Technology Overview
Table 6.8 Bausch and Lomb: Product Portfolio
Table 6.9 Bausch and Lomb: Recent Developments and Future Outlook
Table 6.10 EyePoint Pharmaceuticals: Company Overview
Table 6.11 EyePoint Pharmaceuticals: Technology Overview
Table 6.12 EyePoint Pharmaceuticals: Product Portfolio
Table 6.13 EyePoint Pharmaceuticals: Recent Developments and Future Outlook
Table 6.14 Genentech: Company Overview
Table 6.15 Genentech: Technology Overview
Table 6.16 Genentech: Product Portfolio
Table 6.17 Glaukos: Company Overview
Table 6.18 Glaukos: Technology Overview
Table 6.19 Glaukos: Product Portfolio
Table 6.20 Glaukos: Recent Developments and Future Outlook
Table 6.21 Neurotech Pharmaceuticals: Company Overview
Table 6.22 Neurotech Pharmaceuticals: Technology Overview
Table 6.23 Neurotech Pharmaceuticals: Product Portfolio
Table 6.24 Ocular Therapeutix: Company Overview
Table 6.25 Ocular Therapeutix: Technology Overview
Table 6.26 Ocular Therapeutix: Product Portfolio
Table 6.27 Ocular Therapeutix: Recent Developments and Future Outlook
Table 7.1 Novel Ocular Drug Delivery Devices: List of Clinical Trials
Table 8.1 Novel Ocular Drug Delivery Devices: List of Partnerships and Collaborations, 2012-2021
Table 9.1 Novel Ocular Drug Delivery Devices: Funding and Investments, Pre-2011-2021
Table 9.2 Novel Ocular Drug Delivery Devices: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (In terms of Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (In terms of Number of Citations)
Table 13.1 Eximore: Company Snapshot
Table 13.2 Oculinea: Company Snapshot
Table 14.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
Table 14.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
Table 14.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
Table 14.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
Table 14.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
Table 14.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
Table 14.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
Table 14.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
Table 14.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
Table 14.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
Table 14.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
Table 14.12 Key Industry Players: Distribution by Number of Devices
Table 14.13 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
Table 14.14 Clinical Trial Analysis: Distribution by Phase of Development
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011-2021
Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 14.18 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
Table 14.19 Clinical Trial Analysis: Distribution by Study Design
Table 14.20 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 14.21 Clinical Trial Analysis: Distribution by Target Indication
Table 14.22 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.23 Most Active Players: Distribution by Number of Registered Trials
Table 14.24 Clinical Trial Analysis: Distribution by Geography
Table 14.25 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.28 Most Active Players: Distribution by Number of Partnerships
Table 14.29 Partnerships and Collaborations: Distribution by Region
Table 14.30 Partnerships and Collaborations: Distribution by Country
Table 14.31 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
Table 14.32 Funding and Investment Analysis: Cumulative Distribution by Amount Invested and Year (USD Million)
Table 14.33 Funding and Investment Analysis: Distribution by Type of Funding
Table 14.34 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
Table 14.35 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding, Pre-2011-2021(USD Million)
Table 14.36 Most Active Players: Distribution by Number of Funding Instances
Table 14.37 Funding and Investment Analysis: Distribution by Type of Investor
Table 14.38 Most Active Investors: Distribution by Number of Funding Instances
Table 14.39 Funding and Investment Analysis: Distribution by Geography
Table 14.40 Patent Analysis: Distribution by Type of Patent
Table 14.41 Patent Analysis: Distribution by Year of Publication, 2002-2021
Table 14.42 Patent Analysis: Distribution by Geography
Table 14.43 Patent Analysis: Distribution by Jurisdiction
Table 14.44 Patent Analysis: Distribution by CPC Symbols
Table 14.45 Patent Analysis: Distribution by Type of Drug Delivery Device
Table 14.46 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.47 Leading Industry Players: Distribution by Number of Patents
Table 14.48 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.49 Leading Patent Assignees: Distribution by Number of Patents
Table 14.50 Patent Analysis: Distribution by Patent Age
Table 14.51 Novel Ocular Drug Delivery Devices: Patent Valuation
Table 14.52 Global Novel Ocular Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.53 Novel Ocular Drug Delivery Market for Implants, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.54 Novel Ocular Drug Delivery Market for Inserts, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.55 Novel Ocular Drug Delivery Market for Punctal Plugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.56 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
Table 14.57 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
Table 14.58 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
Table 14.59 Novel Ocular Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.60 Novel Ocular Drug Delivery Devices Market for Implants in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.61 Novel Ocular Drug Delivery Devices Market for Inserts in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.62 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.63 Novel Ocular Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.64 Novel Ocular Drug Delivery Devices Market for Implants in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.65 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.66 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.67 Novel Ocular Drug Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.68 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.69 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.70 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.71 Novel Ocular Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.72 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.73 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 14.74 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Companies Mentioned
- 20/20 OptimEyes Technologies
- 23andMe
- Aciont
- AcuFocus
- Adaptive Biotechnologies
- Aerie Pharmaceuticals
- Aero Pump
- AffaMed Therapeutics
- Akarna Therapeutics
- Alcon
- Alcon
- Alibaba Health Information Technology
- Alimera Sciences
- Allergan
- Alta Partners
- Amorphex Therapeutics
- Angiotech Pharmaceuticals
- Anthrogenesis
- Ascension Ventures
- Atalanta
- Avedro
- Avizorex Pharma
- Bausch & Lomb
- Brien Holden Vision Institute (BHVI)
- BioHealthWays
- Bionic Vision Technologies
- Brandon Capital partners
- BTG
- Burrill & Company
- Cella Therapeutics
- Children's National Hospital
- ChromaGen Vision
- Cirle
- Clarus Ventures
- Clearside Biomedical
- Corporate Renaissance Group
- D. Western Therapeutics Institute
- Deerfield
- DelSiTech
- Department of Defense
- Domain Associates
- DSM
- Envisia Therapeutics
- Escalon Medical
- EW Healthcare Partners
- Eximore
- EYE-GO
- EyePoint Pharmaceuticals
- Eyevensys
- FB VISION
- Fjord Ventures
- Foundry Therapeutics
- Frazier Healthcare Partners
- Genentech
- Genesis Therapeutics
- Glaukos
- Graybug Vision
- Gund Investment
- Gyroscope Therapeutics
- Heptares Therapeutics
- Horizon Discovery
- Horus Pharma
- IDVentures
- IDA Ireland
- Imbio
- ImprimisRx
- Incept
- InterWest Partners
- Intratus
- Invest Michigan
- IQVIA
- Johnson & Johnson Vision
- Kala Pharmaceuticals
- Kedalion Therapeutics
- Kineta
- Knight Therapeutics
- Kodiak Sciences
- Laboratoires Thea
- Laurus Labs
- LayerBio
- Lodo Therapeutics
- M25
- Mati Therapeutics
- MEAgate
- Medical Research Commercialisation Fund (MRCF)
- Medis
- Merck
- Mercury Fund
- Meritech Capital Partners
- Microchip Technology
- Micropore Technologies
- MilliporeSigma
- Modulight
- Monash Vision Group
- Montreaux Growth Partners
- MuPharma
- Mystic Pharmaceuticals
- Nanomerics
- Nanyang Technological University
- National Institutes of Health (NIH)
- Nemera
- Neurotech Pharmaceuticals
- Nicox
- Novaer
- Novaliq
- Novartis
- NuMedii
- Occlugel
- Ocular Therapeutix
- Oculex Pharmaceuticals
- Ocumension Therapeutics
- Oncimmune
- OneOncology
- Opharmic Technology
- OPHTEC
- OrbiMed Advisors
- Orsini Specialty Pharmacy
- Osage University Partners
- Paris Diderot University
- PatientFi
- Pieris Pharmaceuticals
- Pixium Vision
- Polaris Partners
- PolyActiva
- PSIMedica
- Purdue Pharma
- QLT Plug Delivery
- Quadra Logic Tech
- Qura
- Ramot at Tel Aviv University
- Ramscor
- Quadra Logic Technologies
- Re-Vana Therapeutics
- Red Cedar Ventures
- Redwood Pharma
- Regeneron
- Relay Therapeutics
- Ribometrix
- Ripple Therapeutics
- Roche
- Rosalind Advisors
- Rugen Therapeutics
- S K Pharmaceuticals
- Santen Pharmaceutical
- Second Sight
- Societa Industria Farmaceutica Italiana (SIFI)
- Sofinnova Ventures
- Sparta Systems
- SpringTime Ventures
- STADA Arzneimittel
- Sun Ophthalmics
- SurModics
- Sustained Nano Systems
- SV Life Sciences
- SWK Holdings Corporation
- Taiwan Liposome Company
- TALLC
- TARGET PharmaSolutions
- Tempest Therapeutics
- TerraCycle
- TPG Capital
- The French National Centre for Scientific Research
- Théa Open Innovation
- TheraKine
- Tufts University
- UCL Business
- University of Arizona
- University of California
- University of California
- University of Cincinnati
- University of Coimbra
- University of Colorado Board of Regents
- University of Illinois
- University of Maryland
- University of Michigan
- University of Northwestern
- University of Pennsylvania
- University of Pittsburgh
- University of the Witwatersrand
- Versant Ventures
- ViSci
- Vision Source
- Visionex Technologies
- X Chem
- Yuuwa Capital
Methodology
LOADING...
